Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment ...Show More
investor of
Metrics
marketSTOCKS
msh_idCOM:RADIUSPHARM
localeus
websitehttps://radiuspharm.com/
ipo_date2014-06-06
primary_stock_msh_idNASDAQ:RDUS
source_ref9cfe7c37-43c3-4911-9f18-b050a3157774
products_or_servicesThe company offers innovative medicines, including TYMLOS® and BINOSTO®, and provides various patient assistance resources.